Industry & Community · 12 Nov 2026
Samsung Biologics Secures PolyPeptide Group in $1.8 Billion Deal: What the Largest Korean Pharma Acquisition Means for Global Peptide CDMO Supply
Samsung Biologics has secured approximately 98% of PolyPeptide Group's shares in a CHF 1.46 billion tender offer, with its supporting rights offering closing on 11 November at a 96.8% subscription rate. The deal — the largest pharmaceutical acquisition in South Korean history — combines one of the world's leading biologics CDMOs with a specialist peptide API manufacturer, with direct implications for global supply chain capacity and UK research procurement.
9 sources cited
Key takeaways
- Samsung Biologics secured a 97.98% acceptance rate in its tender offer for PolyPeptide Group, a global peptide API contract development and manufacturing organisation (CDMO), clearing the threshold for a full squeeze-out of remaining minority shareholders.
- The acquisition — valued at approximately CHF 1.46 billion (roughly $1.8 billion) — is the largest merger and acquisition deal in South Korean pharmaceutical and biotechnology history.
- Samsung Biologics' supporting rights offering, which raised approximately KRW 2.67 trillion (~$1.8 billion) to finance the transaction, closed on 11 November at a 96.8% subscription rate, signalling strong investor confidence.
- Settlement of the tender offer is pending regulatory approvals across Europe, India, Australia, and Brazil; completion is expected by end of 2026 or early 2027.
- For UK research procurement teams, the deal consolidates a key supplier of peptide APIs under a larger Korean manufacturing group, with potential medium-term implications for pricing, capacity allocation, and supply reliability.
Background: who are the parties?
Samsung Biologics is South Korea's largest contract biologics manufacturer, with operations focused primarily on monoclonal antibody production at scale. Its core services range from late discovery to large-scale commercial manufacturing. Until this acquisition, the company's modality portfolio was largely antibody-centric.
PolyPeptide Group is a Switzerland-headquartered peptide API specialist with manufacturing sites across Europe and North America. The company has long served as a critical upstream supplier for pharmaceutical-grade peptide active pharmaceutical ingredients, including GLP-1 analogues and other therapeutic peptides used in both approved medicines and research settings.
In July 2026, Samsung Biologics announced it would acquire Swiss peptide CDMO PolyPeptide Group for approximately 1.46 billion Swiss francs, in what was described as the largest merger and acquisition in the history of South Korea's pharmaceutical and biotechnology industry.
The tender offer result and rights offering
Samsung Biologics secured a 97.98% acceptance rate in its tender offer for PolyPeptide Group, a global peptide contract development and manufacturing organisation, moving a step closer to full ownership after clearing the threshold for a squeeze-out of remaining shares.
The offer was made through Samsung Peptide, a special purpose company set up as a subsidiary to carry out the acquisition, at 44.31 Swiss francs per share.
To finance the transaction, Samsung Biologics conducted a rights offering that reached a close on 11 November 2026. Samsung Biologics drew a 96.8% subscription rate in its 2.67 trillion won rights offering to fund the PolyPeptide Group acquisition, with existing shareholders subscribing at a rate of 98.7% and an employee fund taking 89.3%.
The company is seeking regulatory approvals from authorities in Europe, India, Australia, and Brazil, and will pay the acquisition price within 10 trading days of clearance. Samsung Biologics expects the transaction to close by the end of 2026 or in early 2027.
Samsung Biologics plans to proceed with the compulsory acquisition of remaining minority shareholder stakes to ultimately secure 100% ownership.
Strategic rationale: pivoting to peptide API manufacturing
The logic underpinning the acquisition reflects a structural shift in demand across the pharmaceutical industry. Meritz Securities evaluated that if Samsung Biologics acquires PolyPeptide Group, it will signify an expansion of its business scope from an antibody-centric model to a peptide CDMO, where demand has recently increased for obesity treatments.
Analysts have advised caution on near-term financial metrics. Kim Jun-young and Kim Hyun-bi, research analysts at Meritz Securities, explained that Samsung Biologics' consolidated operating profit margin could be diluted in the early stages of the acquisition due to high local production costs and integration expenses, and noted it needs to be evaluated from the perspective of expanding global peptide production bases and customer base, rather than short-term profit contribution.
The deal also carries geopolitical context. Companies such as Samsung Biologics and Lotte Biologics have been viewed as potential beneficiaries of regulatory pressure on Chinese biotech firms, with expectations that US clients seeking to diversify production outside China would create new contract opportunities for South Korean companies.
Separately, independent industry analysis suggests that the broader peptide CDMO investment landscape requires careful scrutiny. Peptide investment remains commercially credible but unevenly de-risked: while Divi's has validation supplies and customer-directed equipment, Shilpa Medicare explicitly acknowledged that its planned peptide capacity does not yet have firm orders. The PolyPeptide Group, by contrast, has an established customer base in approved pharmaceutical manufacturing, which may make integration smoother.
Implications for UK research procurement
For UK-based research organisations procuring peptide APIs, the Samsung–PolyPeptide combination carries several near-term considerations.
Supply continuity. Settlement of the tender offer, originally indicated for November 13, 2026, has been postponed pending regulatory approvals in several countries, and Samsung Biologics has not yet disclosed integration plans, capacity investments, or changes to PolyPeptide's operations. Until integration plans are made public, procurement teams should not assume any immediate change to ordering processes or lead times. Standard practice — maintaining at least 60–90 days of safety stock for critical research peptides, and securing alternative qualified suppliers — remains advisable.
Pricing dynamics. The absorption of a specialised CDMO into a larger manufacturing group can, historically, work in either direction: larger groups may achieve economies of scale that reduce API costs, or they may seek to rationalise customer tiers, prioritising high-volume pharmaceutical clients over smaller research or compounding customers. No pricing changes have been announced.
Regulatory compliance. PolyPeptide Group's existing sites hold European and FDA registration. Under Samsung ownership, those certifications would typically require re-inspection or re-registration review as ownership changes are reported to regulators. Procurement teams sourcing from PolyPeptide Group should request updated certificates of analysis and confirm that site registration status remains current during any transitional period.
Supply chain diversification and the demand surge. The stated motivation for the deal — capturing growth in GLP-1 and obesity peptide manufacturing — reflects a broader industry pressure point. Demand for peptide APIs across therapeutic categories has outpaced manufacturing capacity growth for the past two years. The PolyPeptide Group acquisition gives Samsung a seat at that table, but the capacity itself does not expand overnight. Research suppliers dependent on PolyPeptide Group as an upstream source may face tighter allocation if pharmaceutical contracts are prioritised.
Wider peptide manufacturing context
The Samsung–PolyPeptide transaction is the most prominent in a series of capacity investments reshaping the global peptide supply chain. It follows Samsung Biologics' win of a $1.3 billion US pharmaceutical manufacturing contract earlier in 2026, and comes alongside separate investments by Indian CDMOs — including Divi's Laboratories and Shilpa Medicare — in peptide solid-phase synthesis capacity. The common thread is growing industrial conviction that therapeutic peptide demand, driven by GLP-1-class drugs and next-generation immune-mediated disease targets, will sustain investment returns over the medium term.
For UK research procurement specifically, the central implication is that peptide API supply is becoming a commercially contested space between large pharmaceutical contracts and research-use customers. Procurement strategies that rely on a single CDMO source — particularly one now undergoing ownership transition — carry increased supply-chain risk. Working with suppliers that maintain multi-source API qualification, and requesting supplier qualification questionnaires that capture post-acquisition ownership structures, is prudent practice as the deal moves towards final settlement.
Settlement of the Samsung Biologics–PolyPeptide Group transaction remains subject to regulatory approvals in multiple jurisdictions. Procurement teams should monitor docket updates directly via Samsung Biologics' investor relations communications.
The week's Intelligence in one email, every Friday morning.
Regulatory moves, trial readouts, supply-chain news. No product pitches. Unsubscribe in one click.
More in Industry & Community
Shilpa CDMO's $50 Million Expansion: What India's Latest Peptide Manufacturing Investment Means for UK Research Supply Chains
08 Nov 2026
Samsung Biologics Clears the Tender Threshold: What PolyPeptide's Imminent Delisting Means for Peptide API Supply
31 Oct 2026
No Road Back for Large-Scale GLP-1 Compounding: What the Closing 503B Pathway and Chinese API Scandal Mean for Research Procurement
27 Oct 2026